BELITE BIO INC - AMER

Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting

25 Apr 2023 15:30:00 By Nasdaq GlobeNewswire

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

11 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results

31 Mar 2023 18:03:37 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

31 Mar 2023 11:57:14 By Nasdaq GlobeNewswire

Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

18 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data

20 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022

01 Oct 2022 18:03:33 By Nasdaq GlobeNewswire

Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting

23 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China

16 Sep 2022 07:00:32 By Nasdaq GlobeNewswire

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.

22 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Belite Bio Reports First Half 2022 Operational Highlights and Financial Results

10 Aug 2022 20:51:10 By Nasdaq GlobeNewswire

Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

01 Aug 2022 15:10:00 By Nasdaq GlobeNewswire

Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

19 Jul 2022 15:05:33 By Nasdaq GlobeNewswire

Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

12 May 2022 15:30:00 By Nasdaq GlobeNewswire

Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

05 May 2022 07:00:02 By Nasdaq GlobeNewswire

Belite Bio Announces Closing of $36 Million Initial Public Offering

03 May 2022 15:30:00 By Nasdaq GlobeNewswire

Belite Bio Receives FDA Fast Track Designation For LBS-008

03 May 2022 05:50:00 By Nasdaq GlobeNewswire